title: [Clinical observation of the adverse effects of standardized dust mite allergen preparation in the treatment of allergic rhinitis].
abstract: OBJECTIVE
  To observe the adverse effects of specific immunotherapy (SIT) with standardized dust mite allergen preparation in the treatment of allergic rhinitis.
  
  
  METHODS
  Three hundred and eighty-six patients with allergic rhinitis who received subcutaneous SIT with a standardized dust mite allergen preparation were enrolled in this study. The patients were treated for at least 15 weeks,adverse effects after each injection from dosing phase to maintenance phase were recorded and incidence of adverse effects were analyzed.
  
  
  RESULTS
  Of all the patients,adverse reactions occurred in 42 patients (10. 9%),10 local reactions (2. 6%) and 36 systemic side effects (9. 3%) which included 34 mild ,1 moderate and 1 severe side effects (no fatal) were reported respectively. None had anaphylactic shock. Among three treatment options, incidence of routine program was the highest (21.1%),followed by adult cluster program (11. 9%), adverse effects of children cluster program was the least (1. 5%). The adverse effects often happened in the middle and late phase of does addition period and early phase of maintenance period.
  
  
  CONCLUSIONS
  SIT with standardized dust mite allergen preparation in the treatment of allergic rhinitis is a safe and effective treatment by complying with the guidelines and taking specific interventions.
authors.forename: Huarong
authors.initials: H
authors.lastname: Yi
authors.forename: Yuanhua
authors.initials: Y
authors.lastname: Liu
authors.forename: Jing
authors.initials: J
authors.lastname: Ye
authors.forename: Jieqing
authors.initials: J
authors.lastname: Yu
mesh_terms: D000328:Adult; D000818:Animals; D039741:Antigens, Dermatophagoides / Q000009:adverse effects / Q000627:therapeutic use*; D002648:Child; D003888:Desensitization, Immunologic; D006801:Humans; D007167:Immunotherapy; D039981:Pyroglyphidae; D065631:Rhinitis, Allergic / Q000628:therapy*; D016896:Treatment Outcome
chemical_list: D039741:Antigens, Dermatophagoides